New Results
Transthyretin-stabilizing mutation T119M is not associated with protection against vascular disease or death in the UK Biobank
Margaret M. Parker, Simina Ticau, James Butler, David Erbe, Madeline Merkel, Emre Aldinc, Gregory Hinkle, Paul Nioi
doi: https://doi.org/10.1101/771626
Margaret M. Parker
aAlnylam Pharmaceuticals, Cambridge, MA, USA
Simina Ticau
aAlnylam Pharmaceuticals, Cambridge, MA, USA
James Butler
aAlnylam Pharmaceuticals, Cambridge, MA, USA
David Erbe
aAlnylam Pharmaceuticals, Cambridge, MA, USA
Madeline Merkel
aAlnylam Pharmaceuticals, Cambridge, MA, USA
Emre Aldinc
aAlnylam Pharmaceuticals, Cambridge, MA, USA
Gregory Hinkle
aAlnylam Pharmaceuticals, Cambridge, MA, USA
Paul Nioi
aAlnylam Pharmaceuticals, Cambridge, MA, USA

Article usage
Posted September 21, 2019.
Transthyretin-stabilizing mutation T119M is not associated with protection against vascular disease or death in the UK Biobank
Margaret M. Parker, Simina Ticau, James Butler, David Erbe, Madeline Merkel, Emre Aldinc, Gregory Hinkle, Paul Nioi
bioRxiv 771626; doi: https://doi.org/10.1101/771626
Subject Area
Subject Areas
- Biochemistry (10749)
- Bioengineering (8020)
- Bioinformatics (27205)
- Biophysics (13945)
- Cancer Biology (11088)
- Cell Biology (16002)
- Clinical Trials (138)
- Developmental Biology (8760)
- Ecology (13249)
- Epidemiology (2067)
- Evolutionary Biology (17324)
- Genetics (11667)
- Genomics (15888)
- Immunology (10998)
- Microbiology (26006)
- Molecular Biology (10612)
- Neuroscience (56376)
- Paleontology (417)
- Pathology (1729)
- Pharmacology and Toxicology (2999)
- Physiology (4530)
- Plant Biology (9593)
- Synthetic Biology (2674)
- Systems Biology (6961)
- Zoology (1508)